We found that erlotinib-induced DTP-associated lncRNAs MEG3 and AGAP2-AS1 could be detected in tumor biopsies from nontreated patients, suggesting that these lncRNAs may be overexpressed throughout tumor development and that patients displaying overexpression of these lncRNAs could develop resistance to erlotinib. This evidence concerns the gene AGAP2 and neoplasm.